VJVirtual | The management of oligometastatic and oligoremnant disease with local therapy

Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, TX, discusses the management of oligometastatic and oligoremnant disease with local therapy. Previously, several Phase II trials (NCT01725165, NCT02045446, NCT01446744) have demonstrated the benefit of adding consolidative local therapy to the treatment of oligometastatic disease to OS and PFS. Now, the Phase III NRG-LU002 (NCT03137771) trial involving patients with oligometastatic disease is in the process of assessing whether the OS of patients receiving first-line immunotherapy-based systemic therapy will improve with the addition of local therapy. Dr Iyengar additionally highlights the use of circulating tumor DNA (ctDNA) to better understand the molecular alterations responsible for driving an oligometastatic state and to ultimately personalize and optimize therapies for the management of metastatic disease. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.